Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab

被引:25
|
作者
Chou, Shaun [1 ]
Hwang, Shelley Ji Eun [2 ,3 ]
Carlos, Giuliana [2 ,3 ]
Wakade, Deepal [2 ,3 ]
Fernandez-Penas, Pablo [2 ,3 ]
机构
[1] Westmead Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia
[2] Westmead Hosp, Dept Dermatol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
关键词
PD-1; nivolumab; pembrolizumab; CTLA-4; ipilimumab; immunotherapy; lichenoid inflammation; lichen planus; adverse drug reaction; ADVANCED MELANOMA; METASTATIC MELANOMA; UNTREATED MELANOMA; PEMBROLIZUMAB; NIVOLUMAB; PATHWAY; COHORT; CANCER; SAFETY;
D O I
10.1097/DAD.0000000000000587
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Lichenoid drug reaction is a common adverse reaction in patients taking immune-modulatory agents such as antiprogramed cell death (PD-1) and cytotoxic T lymphocyte antigen-4 agents. The authors describe the clinical and histologic features of lichenoid drug reaction in 20 biopsies from 15 patients on anti-PD-1 agents and 9 biopsies from 7 patients on anti-PD-1 plus ipilimumab therapy. Clinically, all except 2 patients presented with discrete, violaceous exanthematous papules to plaques. The lichenoid inflammation in the majority (18 of 29 biopsies) was florid although histology was quite heterogeneous. Nevertheless, there was frequent involvement of the superficial follicular epithelium and acrosyringium, and also a propensity to blister that occurred in approximately 20% of the biopsies. Occasional patients had disease closely resembling lichen planus, although all of these biopsies had some atypical features for lichen planus such as parakeratosis. Dermal eosinophils were common particularly in those with mild inflammation. The lichenoid reaction was responsive to topical steroid or oral systemic treatment in general, and the anti-PD-1 agent had to be ceased in only one patient.
引用
收藏
页码:23 / 27
页数:5
相关论文
共 50 条
  • [1] Clinical and histologic assessment of lichenoid/interface dermatitis observed in patients with advanced malignancies on anti-Programmed cell Death-1 (anti-PD-1) therapy with or without ipilimumab
    Chou, S.
    Hwang, S.
    Carlos, G.
    Wakade, D.
    Fernandez-Penas
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 12 - 13
  • [2] Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Joseph, Richard W.
    Cappel, Mark
    Goedjen, Brent
    Gordon, Matthew
    Kirsch, Brandon
    Gilstrap, Cheryl
    Bagaria, Sanjay
    Jambusaria-Pahlajani, Anokhi
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (01) : 18 - 22
  • [3] Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer
    Diaz-Perez, Julio A.
    Beveridge, Mara G.
    Victor, Thomas A.
    Cibull, Thomas L.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2018, 45 (06) : 434 - 438
  • [4] Autoimmune diabetes and anti-programmed cell death-1 (anti-PD-1) cancer immunotherapy
    Daltry, S.
    Bujanova, J.
    Cranston, I.
    DIABETIC MEDICINE, 2017, 34 : 102 - 102
  • [5] Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
    Schaberg, Kurt B.
    Novoa, Roberto A.
    Wakelee, Heather A.
    Kim, Jinah
    Cheung, Christine
    Srinivas, Sandhya
    Kwong, Bernice Y.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (04) : 339 - 346
  • [6] Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
    Menzies, A. M.
    Johnson, D. B.
    Ramanujam, S.
    Atkinson, V. G.
    Wong, A. N. M.
    Park, J. J.
    McQuade, J. L.
    Shoushtari, A. N.
    Tsai, K. K.
    Eroglu, Z.
    Klein, O.
    Hassel, J. C.
    Sosman, J. A.
    Guminski, A.
    Sullivan, R. J.
    Ribas, A.
    Carlino, M. S.
    Davies, M. A.
    Sandhu, S. K.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 368 - 376
  • [7] POPULATION PHARMACOKINETICS OF AN ANTI-PD-1 ANTIBODY, PENPULIMAB IN PATIENTS WITH ADVANCED MALIGNANCIES
    Chen, Benchao
    Jin, Xiaoping
    Dong, Yongcheng
    Wang, Max
    Xia, Dennis
    Xia, Michelle
    Li, Baiyong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A471 - A471
  • [8] Anti-PD-1 in patients with advanced malignancies and baseline organ dysfunction.
    Kanz, Bridgette A.
    Pollack, Megan Lynn Hames
    Eroglu, Zeynep
    Johnpulle, Romany Anne Nilanthi
    Horn, Leora
    Rapisuwon, Suthee
    Conry, Robert Martin
    Sosman, Jeffrey Alan
    Puzanov, Igor
    Johnson, Douglas Buckner
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
    Zimmer, Lisa
    Apuri, Susmitha
    Eroglu, Zeynep
    Kottschade, Lisa A.
    Forschner, Andrea
    Gutzmer, Ralf
    Schlaak, Max
    Heinzerling, Lucie
    Krackhardt, Angela M.
    Loquai, Carmen
    Markovic, Svetomir N.
    Joseph, Richard W.
    Markey, Kelly
    Utikal, Jochen S.
    Weishaupt, Carsten
    Goldinger, Simone M.
    Sondak, Vernon K.
    Zager, Jonathan S.
    Schadendorf, Dirk
    Khushalani, Nikhil I.
    EUROPEAN JOURNAL OF CANCER, 2017, 75 : 47 - 55
  • [10] Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma
    Yochum, Zachary A.
    Braun, David
    LANCET, 2024, 404 (10460): : 1280 - 1282